Detalhe da pesquisa
1.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197815
2.
Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
Int J Cancer
; 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38900018
3.
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
Oncologist
; 28(6): 474-478, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36933203
4.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 382(1): 41-50, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31751012
5.
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis.
Future Oncol
; 19(25): 1741-1752, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37283038
6.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656302
7.
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Oncologist
; 26(1): 7-16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852072
8.
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Oncologist
; 25(11): 981-992, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860288
9.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Future Oncol
; 15(26): 3003-3014, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339357
10.
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
Support Care Cancer
; 27(3): 1029-1039, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30116943
11.
The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing-Patient's Willingness-to-Pay: A Brief Report.
JTO Clin Res Rep
; 5(1): 100615, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38292413
12.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nat Med
; 30(3): 716-729, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38351187
13.
Personalizing health care: feasibility and future implications.
BMC Med
; 11: 179, 2013 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23941275
14.
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.
Curr Oncol
; 30(2): 2348-2365, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36826141
15.
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Pharmacoecon Open
; 7(3): 455-467, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36811822
16.
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.
Curr Oncol
; 30(7): 6289-6315, 2023 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37504325
17.
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Curr Oncol
; 30(7): 6473-6496, 2023 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37504336
18.
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
JTO Clin Res Rep
; 4(10): 100562, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37744308
19.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
JTO Clin Res Rep
; 4(11): 100572, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954964
20.
Intracranial Metastatic Disease: Present Challenges, Future Opportunities.
Front Oncol
; 12: 855182, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35330715